Figure 6: Decreased thymic selection of V α 14 NKT cells in CD1-TD mice. In summary, the CD1-TD knock-in mouse showed selective defects in CD1d-mediated antigen presentation. It allowed the ...

8 but direct presentation by DCs of tumor-associated antigen via both MHC class I and II to tumor-specific T cells is less well characterized. The recombinant adenoviral vectors Ad.GFP and Ad ...

As a major component of the suppressive tumor microenvironment ... initiators and excellent antigen presenting cells that conduct immunogenic antigen presentation in situ to robustly activate ...

12–14 In preclinical models, defects ... PD-1 therapy on cancer genomic evolution, including acquired mutations in the genes affecting the interferon pathway and antigen-presentation pathway ...

Tumor antigens are captured and displayed by antigen processing and presentation machinery (APM) on the cell surface by HLA-I, making it possible for CD8 + T cells to eliminate cancer cells.

Deep-learning analysis of H&E images to define three immune phenotypes to reveal loss-of-target in excluded immune cells as a novel resistance mechanism of immune checkpoint inhibitor in non-small ...

YTHDF1 controls the level of proteases that destroy potential tumor antigens. This limits their presentation to T cells. These limits were a problem, He said. But when he and his colleagues ...

Immune checkpoint inhibitors provide durable clinical responses in multiple difficult-to-treat tumor types. The tumor microenvironment, tumor immunogenicity, antigen presentation ... that emergence of ...

including those involved in antigen presentation and immune surveillance. Notably, this mechanistic interaction was found to be cell- and cancer-type agnostic, providing a generalized mechanism of ...

Chimeric antigen receptor–modified T cells are capable of killing even aggressive, treatment-refractory acute leukemia cells in vivo. The emergence of tumor cells that no longer express the ...

Details of the presentation are ... CB21 is a highly-potent T-cell engager molecule that targets LY6G6D, an emerging, next-generation tumor-specific antigen for treating colorectal cancer (CRC ...

“The insertion of the α1,3GT gene into NDV enabled infected tumor cells to express exogenous αGal antigen, eliciting a rapid and robust humoral and cellular immune response,” Dr Zhao’s ...